Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Antibody-drug-conjugate-focused Seattle Genetics is shelling out roughly $614 million in cash to acquire Cascadian Therapeutics, a Seattle-based biotech focused on oncology. The centerpiece of the deal is tucatinib, a HER2 receptor inhibitor currently in Phase II trials as a treatment for people with HER2+ metastatic breast cancer. While two approved drugs, the antibody Herceptin and the antibody-drug conjugate Kadcyla, also target the HER2 receptor, tucatinib is an orally available small molecule, licensed to Cascadian from Array BioPharma.
This article has been sent to the following recipient: